newsfilter
← Latest News
PR Newswire·

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

  • China SXT Pharmaceuticals Inc. entered a definitive agreement to sell 8,000,000 Class A ordinary shares or pre-funded warrants to institutional investors at $1.50 per share.
  • The company will issue 8,000,000 warrants with a $1.50 exercise price that are immediately exercisable & have a one-year term.
  • Each warrant includes a zero cash exercise option allowing holders to acquire up to 9 Class A shares.
  • The registered direct offering is expected to generate approximately $12 million in gross proceeds before fees & expenses.
  • Investors have an additional purchase right to acquire up to $12 million of securities on the same terms within 30 days after closing.
  • The offering is scheduled to close on or about October 9, 2026, subject to customary closing conditions.
  • Univest Securities LLC is acting as the sole placement agent for the transaction.
  • The offering was made pursuant to a shelf registration statement on Form F-3 that became effective on December 1, 2025.